MAM
JANX icon

Meeder Asset Management’s Janux Therapeutics JANX Stock Holding History

Meeder Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,972
Closed -$159K – 972
2024
Q4 		$159K Buy
+2,972
New +$157K 0.01% 236

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Meeder Asset Management's JANX Position: Q1 2025 in Review

Meeder Asset Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 2,972 shares — an estimated $159K sold.

Meeder Asset Management first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $159K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Meeder Asset Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Meeder Asset Management sold 2,972 Janux Therapeutics shares in Q1 2025, an estimated $159K.
  • Meeder Asset Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Meeder Asset Management's Janux Therapeutics position peaked at $159K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Meeder Asset Management's 13F filing for Q1 2025, filed 7 May 2025.